Standard treatment regime required for blebitis

Article

A standard treatment regime is required for the management of blebitis.

A standard treatment regime is required for the management of blebitis, revealed a study featured in the British Journal of Ophthalmology.

The anonymous survey was conducted by Dr Patrick Chiam et al., Ophthalmology Department, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, UK, and included 13 questions determining blebitis management. The χ2 analysed any correlations that occurred amongst the participants' answers to the questionnaire.

Data from 68 of the 112 questionnaires, answered by glaucoma consultants, was used in the investigation. It was recorded that 55% of consultants admitted blebitis patients to hospital. A conjuncitval swab was administered to 74% of the patients and 28% were treated with instil iodine on the conjunctiva.

A further 34% of consultants used topical fluroquinolone monotherapy, 28% used cefuroxime and gentamicin, 18% administered fluroquinolone with cefuroxime and 9% used ceftazidime and vancomycin.

Oral antibiotics are prescribed by 69% of consultants and the only antibiotic used is fluroquinolones. Topical corticosteroids are used by 82% of conulstants and 91% use a topical cycloplegic.

Of the consultants who completed the survey, 23% treat blebitis as endophthalmitis, with or without anterior chamber (AC) activity. A further 38% would treat blebitis as endophthalmitis if AC activity was moderate and 34% would if AC activity was severe.

The investigation suggests that, due to the existence of a wide variation in blebitis management regimes, a standard treatment regime is needed.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.